Recent studies show that Arf, a bona fide tumor suppressor, also plays an essential role during mouse eye development. Tgfβ is required for Arf promoter activation in developing mouse eyes, and its capacity to induce Arf depends on Smads 2/3 as well as p38 Mapk. Substantial delay between activation of these pathways and increased Arf transcription imply that changes in the binding of additional transcription factors help orchestrate changes in Arf expression. Focusing on proteins with putative DNA binding elements near the mouse Arf transcription start, we now show that Tgfβ induction of this gene correlated with decreased expression and DNA binding of C/ebpβ to the proximal Arf promoter. Ectopic expression of C/ebpβ in mouse embryo fibroblasts (MEFs) blocked Arf induction by Tgfβ. Although basal levels of Arf mRNA were increased by C/ebpβ loss in MEFs and in the developing eye, Tgfβ was still able to increase Arf, indicating that derepression was not the sole factor. Chromatin immunoprecipitation (ChIP) assay showed increased Sp1 binding to the Arf promotor at 24 and 48 hours after Tgfβ treatment, at which time points Arf expression was significantly induced by Tgfβ. Chemical inhibition of Sp1 and its knockdown by RNA interference blocked Arf induction by Tgfβ in MEFs. In summary, our results indicate that C/ebpβ and Sp1 are negative and positive Arf regulators that are influenced by Tgfβ.
References
[1]
Quelle DE, Zindy F, Ashmun RA, Sherr CJ (1995) Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993–1000.
[2]
Zhang Y, Xiong Y, Yarbrough WG (1998) ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92: 725–734.
[3]
Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, et al. (1997) Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91: 649–659.
[4]
Esteller M, Cordon-Cardo C, Corn PG, Meltzer SJ, Pohar KS, et al. (2001) p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2. Cancer Res 61: 2816–2821.
[5]
Xing EP, Nie Y, Song Y, Yang GY, Cai YC, et al. (1999) Mechanisms of inactivation of p14ARF, p15INK4b, and p16INK4a genes in human esophageal squamous cell carcinoma. Clin Cancer Res 5: 2704–2713.
[6]
Zindy F, Quelle DE, Roussel MF, Sherr CJ (1997) Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene 15: 203–211.
[7]
Freeman-Anderson NE, Zheng Y, McCalla-Martin AC, Treanor LM, Zhao YD, et al. (2009) Expression of the Arf tumor suppressor gene is controlled by Tgfbeta2 during development. Development 136: 2081–2089.
[8]
Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M (1999) The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 397: 164–168.
[9]
Pasmant E, Laurendeau I, Heron D, Vidaud M, Vidaud D, et al. (2007) Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF. Cancer Res 67: 3963–3969.
[10]
Yap KL, Li S, Munoz-Cabello AM, Raguz S, Zeng L, et al. (2010) Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell 38: 662–674.
[11]
Parisi T, Pollice A, Di Cristofano A, Calabro V, La Mantia G (2002) Transcriptional regulation of the human tumor suppressor p14(ARF) by E2F1, E2F2, E2F3, and Sp1-like factors. Biochem Biophys Res Commun 291: 1138–1145.
[12]
Komori H, Enomoto M, Nakamura M, Iwanaga R, Ohtani K (2005) Distinct E2F-mediated transcriptional program regulates p14ARF gene expression. EMBO J 24: 3724–3736.
[13]
Elliott MJ, Dong YB, Yang H, McMasters KM (2001) E2F-1 up-regulates c-Myc and p14(ARF) and induces apoptosis in colon cancer cells. Clin Cancer Res 7: 3590–3597.
[14]
del Arroyo AG, El Messaoudi S, Clark PA, James M, Stott F, et al. (2007) E2F-dependent induction of p14ARF during cell cycle re-entry in human T cells. Cell Cycle 6: 2697–2705.
[15]
Inoue K, Roussel MF, Sherr CJ (1999) Induction of ARF tumor suppressor gene expression and cell cycle arrest by transcription factor DMP1. Proc Natl Acad Sci U S A 96: 3993–3998.
[16]
Sreeramaneni R, Chaudhry A, McMahon M, Sherr CJ, Inoue K (2005) Ras-Raf-Arf signaling critically depends on the Dmp1 transcription factor. Mol Cell Biol 25: 220–232.
[17]
Ameyar-Zazoua M, Wisniewska MB, Bakiri L, Wagner EF, Yaniv M, et al. (2005) AP-1 dimers regulate transcription of the p14/p19ARF tumor suppressor gene. Oncogene 24: 2298–2306.
[18]
Maeda T, Hobbs RM, Merghoub T, Guernah I, Zelent A, et al. (2005) Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature 433: 278–285.
[19]
Bouchard C, Lee S, Paulus-Hock V, Loddenkemper C, Eilers M, et al. (2007) FoxO transcription factors suppress Myc-driven lymphomagenesis via direct activation of Arf. Genes Dev 21: 2775–2787.
[20]
McKeller RN, Fowler JL, Cunningham JJ, Warner N, Smeyne RJ, et al. (2002) The Arf tumor suppressor gene promotes hyaloid vascular regression during mouse eye development. Proc Natl Acad Sci U S A 99: 3848–3853.
[21]
Silva RL, Thornton JD, Martin AC, Rehg JE, Bertwistle D, et al. (2005) Arf-dependent regulation of Pdgf signaling in perivascular cells in the developing mouse eye. EMBO J 24: 2803–2814.
[22]
Zheng Y, Zhao YD, Gibbons M, Abramova T, Chu PY, et al. (2010) Tgfbeta signaling directly induces Arf promoter remodeling by a mechanism involving Smads 2/3 and p38 MAPK. J Biol Chem 285: 35654–35664.
[23]
Sanford LP, Ormsby I, Gittenberger-de Groot AC, Sariola H, Friedman R, et al. (1997) TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes. Development 124: 2659–2670.
[24]
Screpanti I, Romani L, Musiani P, Modesti A, Fattori E, et al. (1995) Lymphoproliferative disorder and imbalanced T-helper response in C/EBP beta-deficient mice. EMBO J 14: 1932–1941.
[25]
Widau RC, Zheng Y, Sung CY, Zelivianskaia A, Roach LE, et al. (2012) p19Arf represses platelet-derived growth factor receptor beta by transcriptional and posttranscriptional mechanisms. Mol Cell Biol 32: 4270–4282.
[26]
Ewing SJ, Zhu S, Zhu F, House JS, Smart RC (2008) C/EBPbeta represses p53 to promote cell survival downstream of DNA damage independent of oncogenic Ras and p19(Arf). Cell Death Differ 15: 1734–1744.
[27]
Sherr CJ, DePinho RA (2000) Cellular senescence: mitotic clock or culture shock? Cell 102: 407–410.
[28]
Ramji DP, Foka P (2002) CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem J 365: 561–575.
[29]
Descombes P, Schibler U (1991) A liver-enriched transcriptional activator protein, LAP, and a transcriptional inhibitory protein, LIP, are translated from the same mRNA. Cell 67: 569–579.
[30]
Liu S, Croniger C, Arizmendi C, Harada-Shiba M, Ren J, et al. (1999) Hypoglycemia and impaired hepatic glucose production in mice with a deletion of the C/EBPbeta gene. J Clin Invest 103: 207–213.
[31]
DeGregori J, Leone G, Miron A, Jakoi L, Nevins JR (1997) Distinct roles for E2F proteins in cell growth control and apoptosis. Proc Natl Acad Sci U S A 94: 7245–7250.
[32]
Bates S, Phillips AC, Clark PA, Stott F, Peters G, et al. (1998) p14ARF links the tumour suppressors RB and p53. Nature 395: 124–125.
[33]
Robertson KD, Jones PA (1998) The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. Mol Cell Biol 18: 6457–6473.
[34]
Ma Y, Kurtyka CA, Boyapalle S, Sung SS, Lawrence H, et al. (2008) A small-molecule E2F inhibitor blocks growth in a melanoma culture model. Cancer Res 68: 6292–6299.
[35]
Blume SW, Snyder RC, Ray R, Thomas S, Koller CA, et al. (1991) Mithramycin inhibits SP1 binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo. J Clin Invest 88: 1613–1621.
[36]
Koziczak M, Krek W, Nagamine Y (2000) Pocket protein-independent repression of urokinase-type plasminogen activator and plasminogen activator inhibitor 1 gene expression by E2F1. Mol Cell Biol 20: 2014–2022.
[37]
Briggs MR, Kadonaga JT, Bell SP, Tjian R (1986) Purification and biochemical characterization of the promoter-specific transcription factor, Sp1. Science 234: 47–52.
[38]
Dynan WS, Tjian R (1983) The promoter-specific transcription factor Sp1 binds to upstream sequences in the SV40 early promoter. Cell 35: 79–87.
[39]
Zhang HJ, Li WJ, Yang SY, Li SY, Ni JH, et al. (2009) 8-Chloro-adenosine-induced E2F1 promotes p14ARF gene activation in H1299 cells through displacing Sp1 from multiple overlapping E2F1/Sp1 sites. J Cell Biochem 106: 464–472.
[40]
Zhu S, Yoon K, Sterneck E, Johnson PF, Smart RC (2002) CCAAT/enhancer binding protein-beta is a mediator of keratinocyte survival and skin tumorigenesis involving oncogenic Ras signaling. Proc Natl Acad Sci U S A 99: 207–212.
[41]
Feng XH, Lin X, Derynck R (2000) Smad2, Smad3 and Smad4 cooperate with Sp1 to induce p15(Ink4B) transcription in response to TGF-beta. EMBO J 19: 5178–5193.
[42]
Li JM, Nichols MA, Chandrasekharan S, Xiong Y, Wang XF (1995) Transforming growth factor beta activates the promoter of cyclin-dependent kinase inhibitor p15INK4B through an Sp1 consensus site. J Biol Chem 270: 26750–26753.
[43]
Jungert K, Buck A, von Wichert G, Adler G, Konig A, et al. (2007) Sp1 is required for transforming growth factor-beta-induced mesenchymal transition and migration in pancreatic cancer cells. Cancer Res 67: 1563–1570.
[44]
Karlseder J, Rotheneder H, Wintersberger E (1996) Interaction of Sp1 with the growth- and cell cycle-regulated transcription factor E2F. Mol Cell Biol 16: 1659–1667.
[45]
Aslanian A, Iaquinta PJ, Verona R, Lees JA (2004) Repression of the Arf tumor suppressor by E2F3 is required for normal cell cycle kinetics. Genes Dev 18: 1413–1422.
[46]
Marin M, Karis A, Visser P, Grosveld F, Philipsen S (1997) Transcription factor Sp1 is essential for early embryonic development but dispensable for cell growth and differentiation. Cell 89: 619–628.
[47]
Sherr CJ (2012) Ink4-Arf Locus in Cancer and Aging. Wiley Interdiscip Rev Dev Biol 1: 731–741.
[48]
Yu YS, Chang BL (1997) Persistent hyperplastic primary vitreous in male twins. Korean J Ophthalmol 11: 123–125.
[49]
Lin AE, Biglan AW, Garver KL (1990) Persistent hyperplastic primary vitreous with vertical transmission. Ophthalmic Paediatr Genet 11: 121–122.
[50]
Wang MK, Phillips CI (1973) Persistent hyperplastic primary vitreous in non-identical twins. Acta Ophthalmol (Copenh) 51: 434–437.
[51]
Sebastian T, Johnson PF (2009) RasV12-mediated down-regulation of CCAAT/enhancer binding protein beta in immortalized fibroblasts requires loss of p19Arf and facilitates bypass of oncogene-induced senescence. Cancer Res 69: 2588–2598.
[52]
Sebastian T, Malik R, Thomas S, Sage J, Johnson PF (2005) C/EBPbeta cooperates with RB:E2F to implement Ras(V12)-induced cellular senescence. EMBO J 24: 3301–3312.
